Mangoceuticals (MGRX) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was $133,368, down 45.6% year-over-year due to delays from a telehealth platform migration.

• Net loss for Q3 2024 was $1,999,694, an 11.1% increase from Q3 2023, driven by higher stock-based compensation and interest expense.

• For the nine months ended September 30, 2024, revenue grew 4.8% to $510,626, but net loss widened slightly to $6,758,630.

• The company completed a 1-for-15 reverse stock split in October 2024 to regain Nasdaq compliance.

• A $20 million patent acquisition was completed, funded mainly by Series C Preferred Stock issuance.

Financial highlights

• Q3 2024 gross profit was $82,671, down from $144,589 in Q3 2023.

• Operating expenses for Q3 2024 were $1,840,745, a slight decrease from $1,944,049 in Q3 2023.

• For the nine months ended September 30, 2024, gross profit was $299,861 and operating expenses totaled $6,594,193.

• Cash and cash equivalents were $73,912 as of September 30, 2024, down from $739,006 at year-end 2023.

• Accumulated deficit reached $17,985,966 as of September 30, 2024.

Outlook and guidance

• Management anticipates the need for additional funding to continue operations and support growth over the next 12 months.

• The company is pursuing strategic alternatives, including potential business combinations or asset sales.

• Plans include expanding product offerings, enhancing technology, and seeking acquisitions in the health and wellness sector.